<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946541</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_DMM_III</org_study_id>
    <nct_id>NCT02946541</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Evogliptin After Oral Administration in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, phase III clinical trial to
      investigate the efficacy and safety of evogliptin after oral administration in patients with
      type 2 diabetes who have inadequate glycemic control on diet and exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Evogliptin 5mg Group: Administration with Evogliptin 5mg for 0-52 weeks.

        2. Placebo Group: Administration with Placebo for 0-24 weeks, and with Evogliptin 5mg for
           24-52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Change from baseline at 24 weeks</time_frame>
    <description>unit: %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting plasma glucose</measure>
    <time_frame>Change from baseline at 24 weeks</time_frame>
    <description>unit: mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c response rate</measure>
    <time_frame>Change from baseline at 24 weeks</time_frame>
    <description>unit: %</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>evogliptin 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evogliptin 5mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evogliptin 5mg</intervention_name>
    <description>evogliptin 5mg, QD</description>
    <arm_group_label>evogliptin 5mg</arm_group_label>
    <other_name>DA-1229</other_name>
    <other_name>Suganon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, QD</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with 6.5%≤HbA1c≤10.0% at screening

          -  Subjects untreated with oral hypoglycemic agents within 6 weeks prior to screening

          -  Subjects with 6.5%≤HbA1c≤10.0% at Visit 2

          -  Subjects with 20kg/m2≤BMI≤40kg/m2 at screening

        Exclusion Criteria:

          -  Subjects with fasting plasma glucose≥270mg/dL at screening

          -  Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational
             diabetes mellitus

          -  Subjects with history of myocardial infarction, cerebral infarction within 6 months
             prior to screening

          -  Subjects with ALT and AST 2.5 times or higher than upper normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doo Man Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>March 26, 2017</last_update_submitted>
  <last_update_submitted_qc>March 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DA-1229</keyword>
  <keyword>evogliptin</keyword>
  <keyword>DPP-IV inhibitor</keyword>
  <keyword>Suganon</keyword>
  <keyword>DPP-4 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

